MELANOMA IN 2015: Immune-checkpoint blockade — durable cancer control

    loading  Checking for direct PDF access through Ovid

Abstract

In 2015, advances in immunotherapy for metastatic melanoma have come to fruition, with phase III data supporting the combination of ipilimumab and nivolumab as first-line therapy. Understanding the mechanisms involved in an effective antitumour immune response are now key to further advances. Several studies published in 2015 have increased our understanding of the complex relationships that exist between our immune system and malignancy.

Related Topics

    loading  Loading Related Articles